Src inhibitors modulate frataxin protein levels

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Friedreich's Ataxia (FRDA) results from defective frataxin expression, leading to premature death.
• Current FRDA treatments are ineffective, highlighting the need for novel therapeutic strategies.
• Metabolic changes in FRDA, such as redox imbalance and ATP deficiency, are linked to tyrosine kinase Src activity.

Purpose of the Study:

• To investigate the role of tyrosine kinase Src in regulating frataxin expression.
• To explore the potential of Src inhibitors as a therapeutic approach for FRDA.

Main Methods:

• Investigated the interaction between Src and frataxin using biochemical assays.
• Utilized cell-based models derived from FRDA patients.
• Assessed the effect of Src inhibitors on frataxin levels and cellular function.

Main Results:

• Src phosphorylates frataxin at Y118, promoting its ubiquitination and degradation.
• Src inhibitors increase frataxin accumulation in FRDA patient-derived cells.
• Src inhibitors rescue the aconitase defect in frataxin-deficient cells.

Conclusions:

• Src signaling pathway is a key regulator of frataxin expression.
• Src inhibitors represent a promising new therapeutic class for FRDA by increasing frataxin levels.
• Targeting Src offers a potential strategy to combat FRDA.